UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 26, 2011**

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-21846	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

8910 University Center Lane, Suite 660 **San Diego, California** (Address of principal executive offices)	**92122** (Zip Code)

Registrant's telephone number, including area code: **(858) 459-7800**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

The Registrant disclosed that on Thursday, May 26, 2011, it made a presentation at the C21 BioVentures Drug Partnering Conference in Napa, California. A copy of the investor presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. Also, the Registrant posted the investor presentation materials to its website (www.aethlonmedical.com) today, May 31, 2011.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

Exhibit No.	Description
99.1	Aethlon C21 Presentation 05-26-11

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.
(Registrant)

Date: May 31, 2011

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation Materials

Exhibit 99.1


aethlon
MEDICAL, INC.
C21 BioVentures Conference
May 26, 2011
Jim Joyce
Chairman, CEO


Forward Looking Statements
MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE ONLINE AT WWW.SEC.GOV OR WWW.AETHLONMEDICAL.COM


Pioneering the Selective
Therapeutic Filtration Industry
aethlon
MEDICAL, INC.


Our objective at C21 is to introduce our
Aethlon ADAPT™ system
aethlon
MEDICAL, INC.


The Aethlon ADAPT™ System
Adaptive Dialysis-like Affinity Platform Technology
• Converges proven plasma filter technology with antibodies or other affinity drug agents
• An extracorporeal therapeutic with a much less burdensome medical device regulatory pathway
aethlon
MEDICAL, INC.


The Aethlon Adapt™ System Repurposes
• Clinical Stage Agents
• Approved Agents
• Clinical Dropouts
aethlon
MEDICAL, INC.

The Hemopurifier®

The first medical device to selectively remove infectious viruses and immunosuppressive toxins from circulation

The Hemopurifier®

A Broad-Spectrum Therapeutic Device

- Hepatitis C
- HIV
- Bioterror & Pandemic Threats
- Cancer Secreted Exosomes

aethlon MEDICAL, INC.

Aethlon ADAPT™ System Advantages

- Allows immediate target clearance without adding drug toxicity or interaction risks to other therapies
- Allows increased dosing of drug agents vs. systemic delivery
- Allows immobilization of an individual or multiple drug agent cocktail within a single therapeutic
- Provides potential diagnostic and biomarker opportunity
- Rapid development cycle


The Medical Device Pathway
An executable commercialization strategy
• United States - FDA
• Safety & Pivotal Study
• European Union – CE Mark
• Safety study that also demonstrates target reduction
• CE mark or FDA approval opens other markets
• India - Practitioner driven market - ERB approval
aethlon
MEDICAL, INC.

Aethlon ADAPT™ system devices can be delivered through an established global infrastructure of dialysis stations (90,000+ in U.S.)

Additional Delivery Infrastructure

- CRRT machines already located in hospitals and clinics
- Portable pump configurations


The Future
Home Delivery of Therapeutic Devices Evolved From The Aethlon ADAPT™ System
aethlon
MEDICAL, INC.


Current Adapt™ System Pipeline
• The Hemopurifier®
• Device to reduce incidence of sepsis
• Proposed in DARPA DLT contract response
• Device to treat sepsis
• Proposed in U.S. Army DLT contract response
• Devices developed through future collaborations
aethlon
MEDICAL, INC.


The Aethlon ADAPT™ System
Adaptive Dialysis-like Affinity Platform Technology
• Converges proven plasma filter technology with antibodies or other affinity drug agents
• An extracorporeal therapeutic with a much less burdensome medical device regulatory pathway
aethlon
MEDICAL, INC.

Presenter Information

Jim Joyce

Chairman, CEO

Aethlon Medical, Inc.

(858) 459-7800 x301

jj@aethlonmedical.com

aethlon MEDICAL, INC.

8910 University Center Lane, Suite 660

San Diego, CA. 92122

www.AethlonMedical.com